Full history for every metric is available with a Kvantra account
RAPT Therapeutics, Inc. (RAPT)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 5 | 4 | 2 | 0 | 0 | 0 |
| Operating profit | $m | -136 | -113 | |||||
| Net profit | $m | -43 | -53 | -69 | -84 | -117 | -130 | -106 |
| EPS reported | $ | -3.19 | -3.08 | |||||
| Operating cashflow per share | $ | -2.04 | -0.88 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -2.05 | -0.88 | |||||
| Free cash flow | $m | -83 | -87 | |||||
| Net debt | $m | -231 | -157 | |||||
| Book value equity | $m | 190 | 152 | |||||
| Book value per share | $ | 4.66 | 5.64 | |||||
| Number of shares | m | 40.76 | 26.96 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.71 | 10.58 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -6.18 | -18.55 | |||||
| EV/EBITDA LTM | x | -2.72 | -13.85 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -25.21% | -2.25% | |||||
| FCF Yield | % | -16.19% | -5.39% | |||||
| Quality | ||||||||
| ROE | % | -68.38% | -22.27% | |||||
| ROIC | % | -70.01% | -25.17% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -18.57 | -33.38 | |||||
| Net Debt/EBITDA | x | 1.28 | 1.01 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -44.85% | -9.79% | |||||
| Net debt/Equity | x | -1.22 | -1.04 | |||||
| Gross debt/equity | x | 0.02 | 0.02 | |||||
Company overview
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. These treatments are aimed at addressing critical unmet medical needs for patients battling oncology and inflammatory diseases. Its primary drug candidate for inflammation, RPT193, functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. This compound works by selectively preventing type 2 T helper cells from migrating into inflamed tissues. In the oncology pipeline, FLX475 stands as the company's leading candidate, also an oral small molecule CCR4 antagonist. This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy both as a standalone treatment and in combination with pembrolizumab for individuals with advanced cancer. RAPT Therapeutics is also engaged in the development of a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Founded in 2015, the company initially operated as FLX Bio, Inc. before rebranding as RAPT Therapeutics, Inc. in May 2019. Its corporate headquarters are situated in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. These treatments are aimed at addressing critical unmet medical needs for patients battling oncology and inflammatory diseases. Its primary drug candidate for inflammation, RPT193, functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. This compound works by selectively preventing type 2 T helper cells from migrating into inflamed tissues. In the oncology pipeline, FLX475 stands as the company's leading candidate, also an oral small molecule CCR4 antagonist. This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy both as a standalone treatment and in combination with pembrolizumab for individuals with advanced cancer. RAPT Therapeutics is also engaged in the development of a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Founded in 2015, the company initially operated as FLX Bio, Inc. before rebranding as RAPT Therapeutics, Inc. in May 2019. Its corporate headquarters are situated in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free